The emergence of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) propelled EGFR-mutated patients of non-small cell lung cancer (NSCLC) into the era of precision medicine. This evidence concerns the gene EGFR and non-small cell lung carcinoma.